UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 866

Sortiert nach

CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape

Cell reports (Cambridge), 2016-04, Vol.15 (3), p.481-489

2016

Volltextzugriff (PDF)

Cellular and molecular mechanisms involved in the establishment of HIV-1 latency

Retrovirology, 2013-02, Vol.10 (1), p.11-11, Article 11

2013

Volltextzugriff (PDF)

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA

Retrovirology, 2015-02, Vol.12 (1), p.22-22, Article 22

2015

Volltextzugriff (PDF)

HIV drug resistance against strand transfer integrase inhibitors

Retrovirology, 2017-06, Vol.14 (1), p.36-36, Article 36

2017

Volltextzugriff (PDF)

The role of unintegrated DNA in HIV infection

Retrovirology, 2011-07, Vol.8 (1), p.52-52, Article 52

2011

Volltextzugriff (PDF)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Viruses, 2015-07, Vol.7 (7), p.3703-3718

2015

Volltextzugriff (PDF)

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance

Virus research, 2017-07, Vol.239, p.1-9

2017

Volltextzugriff (PDF)

Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions

AIDS (London), 2013-04, Vol.27 (7), p.1045-1057

2013

Volltextzugriff (PDF)

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Journal of Virology, 2012-03, Vol.86 (5), p.2696-2705

2012

Volltextzugriff (PDF)

Early HIV treatment to forestall drug resistance

The Lancet infectious diseases, 2016-05, Vol.16 (5), p.512-513

Wainberg, Mark A

2016

Volltextzugriff (PDF)

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Journal of antimicrobial chemotherapy, 2016-08, Vol.71 (8), p.2083-2088

2016

Volltextzugriff (PDF)

What if HIV were unable to develop resistance against a new therapeutic agent?

BMC medicine, 2013-11, Vol.11 (1), p.249-249, Article 249

2013

Volltextzugriff (PDF)

Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication

Scientific reports, 2017-07, Vol.7 (1), p.6345-11, Article 6345

2017

Volltextzugriff (PDF)

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

Journal of medical virology, 2018-05, Vol.90 (5), p.796-802

2018

Volltextzugriff (PDF)

Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors

Journal of antimicrobial chemotherapy, 2017-03, Vol.72 (3), p.727-734

2017

Volltextzugriff (PDF)

Novel therapeutic strategies targeting HIV integrase

BMC medicine, 2012-04, Vol.10 (1), p.34-34, Article 34

2012

Volltextzugriff (PDF)

RIG-I-Mediated Antiviral Signaling Is Inhibited in HIV-1 Infection by a Protease-Mediated Sequestration of RIG-I

Journal of Virology, 2011-02, Vol.85 (3), p.1224-1236

2011

Volltextzugriff (PDF)

High Rates of Forward Transmission Events after Acute/Early HIV-1 Infection

The Journal of infectious diseases, 2007-04, Vol.195 (7), p.951-959

2007

Volltextzugriff (PDF)

We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance

AIDS (London), 2016-11, Vol.30 (17), p.2725-2727

2016

Volltextzugriff (PDF)

Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors

Antimicrobial Agents and Chemotherapy, 2012-10, Vol.56 (10), p.5000-5008

2012

Volltextzugriff (PDF)

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Journal of virology, 2015-03, Vol.89 (6), p.3163-3175

2015

Volltextzugriff (PDF)

Is resistance to dolutegravir possible when this drug is used in first-line therapy?

Viruses, 2014-08, Vol.6 (9), p.3377-3385

2014

Volltextzugriff (PDF)

EDITORIAL COMMENTARY: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome

Clinical infectious diseases, 2015-05, Vol.60 (10), p.1550-1551

Wainberg, Mark A.

2015

Volltextzugriff (PDF)

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Journal of antimicrobial chemotherapy, 2016-07, Vol.71 (7), p.1948-1953

2016

Volltextzugriff (PDF)

Tetherin restricts direct cell-to-cell infection of HIV-1

Retrovirology, 2010-12, Vol.7 (1), p.115-115, Article 115

2010

Volltextzugriff (PDF)

1 – 25 von 866

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(791)
Mit Volltextzugriff
(771)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(599)
Free E-Journal (出版社公開部分のみ）
(592)
Ingenta
(336)
LWW Total
(274)
IngentaConnect Journals
(236)
Publisher or Other Site
(195)
SpringerLink_现刊
(108)
Elsevier ScienceDirect Journals Complete
(84)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(73)
Nexis Uni
(61)
Wiley-Blackwell Full Collection
(59)
Oxford journals
(55)
Ebook Central Perpetual and DDA
(54)
Oxford Journals 2020 Medicine
(49)
JSTOR
(36)
Taylor & Francis Journals
(30)
Taylor & Francis
(30)
SAGE Publications
(22)
Springer Nature - Connect here FIRST to enable access
(21)
Wiley Online Library
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape

Cellular and molecular mechanisms involved in the establishment of HIV-1 latency

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA

HIV drug resistance against strand transfer integrase inhibitors

The role of unintegrated DNA in HIV infection

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance

Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Early HIV treatment to forestall drug resistance

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

What if HIV were unable to develop resistance against a new therapeutic agent?

Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors

Novel therapeutic strategies targeting HIV integrase

RIG-I-Mediated Antiviral Signaling Is Inhibited in HIV-1 Infection by a Protease-Mediated Sequestration of RIG-I

High Rates of Forward Transmission Events after Acute/Early HIV-1 Infection

We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance

Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Is resistance to dolutegravir possible when this drug is used in first-line therapy?

EDITORIAL COMMENTARY: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Tetherin restricts direct cell-to-cell infection of HIV-1

Suchergebnisse filtern